DK0888386T3 - Stabilt faktor VIII/vWF-kompleks - Google Patents

Stabilt faktor VIII/vWF-kompleks

Info

Publication number
DK0888386T3
DK0888386T3 DK97906928T DK97906928T DK0888386T3 DK 0888386 T3 DK0888386 T3 DK 0888386T3 DK 97906928 T DK97906928 T DK 97906928T DK 97906928 T DK97906928 T DK 97906928T DK 0888386 T3 DK0888386 T3 DK 0888386T3
Authority
DK
Denmark
Prior art keywords
factor viii
vwf
stable factor
vwf complex
complexes
Prior art date
Application number
DK97906928T
Other languages
English (en)
Other versions
DK0888386T4 (da
Inventor
Bernhard Fischer
Artur Mitterer
Friedrich Dorner
Johann Eibl
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3492100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0888386(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of DK0888386T3 publication Critical patent/DK0888386T3/da
Publication of DK0888386T4 publication Critical patent/DK0888386T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK97906928T 1996-03-15 1997-03-13 Stabilt faktor VIII/vWF-kompleks DK0888386T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0049496A AT403764B (de) 1996-03-15 1996-03-15 Stabiler faktor viii/vwf-komplex
PCT/AT1997/000055 WO1997034930A1 (de) 1996-03-15 1997-03-13 STABILER FAKTOR VIII/vWF-KOMPLEX

Publications (2)

Publication Number Publication Date
DK0888386T3 true DK0888386T3 (da) 2003-02-17
DK0888386T4 DK0888386T4 (da) 2009-05-11

Family

ID=3492100

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97906928T DK0888386T4 (da) 1996-03-15 1997-03-13 Stabilt faktor VIII/vWF-kompleks

Country Status (10)

Country Link
US (3) US6228613B1 (da)
EP (1) EP0888386B2 (da)
JP (1) JP2000506869A (da)
AT (2) AT403764B (da)
CA (1) CA2248960C (da)
DE (1) DE59708667D1 (da)
DK (1) DK0888386T4 (da)
ES (1) ES2186870T5 (da)
PT (1) PT888386E (da)
WO (1) WO1997034930A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
AT408443B (de) * 1998-02-27 2001-11-26 Immuno Ag Verfahren zur gewinnung von gereinigtem faktor viii:c/vwf-komplex
US6605222B1 (en) * 1998-05-20 2003-08-12 Baxter Aktiengesellschaft Method for producing a factor VIII/von Willebrand factor complex
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
WO2001002853A2 (en) * 1999-07-05 2001-01-11 K.U. Leuven Research & Development DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
DE10246125A1 (de) * 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
WO2004065595A1 (ja) * 2003-01-17 2004-08-05 Ttc Co., Ltd. アフィニティートラップリアクター、及びそれを用いたアンジオスタチン様断片のヒト血漿からの一段階精製プロセス
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
MX2007002085A (es) * 2004-08-20 2007-07-19 Prometic Biosciences Ltd Esquemas de aislamiento y purificacion consecutivos de proteinas mediante cromatografia de afinidad.
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
CA2660310C (en) * 2006-03-30 2015-04-21 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
CN101646779B (zh) 2007-02-23 2014-12-03 Sk化学株式会社 制备和纯化因子viii及其衍生物的方法
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
KR101915445B1 (ko) * 2007-12-28 2018-11-05 박스알타 인코퍼레이티드 단백질의 역압 여과
KR101507718B1 (ko) 2008-06-24 2015-04-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
PT2349314E (pt) * 2008-10-21 2013-05-28 Baxter Int Formulações de vwf recombinante liofilizado
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
WO2012171031A1 (en) * 2011-06-10 2012-12-13 Baxter International Inc. Treatment of coagulation disease by administration of recombinant vwf
WO2013057219A1 (en) 2011-10-18 2013-04-25 Csl Behring Gmbh Method for improving the stability of purified factor viii after reconstitution
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
EP3538134B1 (en) * 2016-11-11 2021-12-29 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
PT3648788T (pt) 2017-07-07 2024-08-23 Takeda Pharmaceuticals Co Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante
WO2021001522A1 (en) * 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
JP2024513983A (ja) * 2021-04-13 2024-03-27 グリフォルス・ワールドワイド・オペレーションズ・リミテッド 第ｖｉｉｉ因子または第ｖｉｉｉ因子／フォン・ヴィレブランド因子複合体を含む液体組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
US5149787A (en) † 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4707441A (en) 1984-08-06 1987-11-17 Technicon Instruments Corp. Binding assays in automated apparatus with liposome compatible surfactants
FR2570276B1 (fr) 1984-09-18 1987-09-04 Immunotech Sa Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant
US5250421A (en) * 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
WO1988005825A1 (en) 1987-01-30 1988-08-11 Biogen N.V. A method for producing factor viii in high yield
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
US5110907A (en) † 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
FR2651437A1 (fr) 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
JP2931655B2 (ja) 1990-09-12 1999-08-09 サントル・レジョナル・ド・トランスフユジョン・サンギン・ド・リール 全血漿から血液疑固▲ｖｉｉｉ▼因子―フオン・ビルブラント因子複合体濃縮物の製造方法
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4204694C3 (de) 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
AT399818B (de) 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
IT1256622B (it) 1992-12-04 1995-12-12 Sclavo Spa Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE19616540A1 (de) 1995-11-10 1997-05-15 Immuno Ag Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex

Also Published As

Publication number Publication date
DK0888386T4 (da) 2009-05-11
ES2186870T3 (es) 2003-05-16
US6924151B2 (en) 2005-08-02
EP0888386B1 (de) 2002-11-06
ATA49496A (de) 1997-10-15
JP2000506869A (ja) 2000-06-06
US7498146B2 (en) 2009-03-03
US20020025556A1 (en) 2002-02-28
AT403764B (de) 1998-05-25
CA2248960A1 (en) 1997-09-25
PT888386E (pt) 2003-03-31
WO1997034930A1 (de) 1997-09-25
EP0888386A1 (de) 1999-01-07
DE59708667D1 (de) 2002-12-12
EP0888386B2 (de) 2009-04-01
US20050209154A1 (en) 2005-09-22
ES2186870T5 (es) 2009-06-19
US6228613B1 (en) 2001-05-08
ATE227310T1 (de) 2002-11-15
CA2248960C (en) 2009-12-15

Similar Documents

Publication Publication Date Title
DK0888386T3 (da) Stabilt faktor VIII/vWF-kompleks
DE69914928D1 (de) Polymerkomplexe von glukuronoglukanen
HN1996000017A (es) Isotiazolonas
DE59603014D1 (de) Verfahren zur herstellung von niedermolekularem, hochreaktivem polyisobuten
DE69704433D1 (de) Herstellung von kohlenwasserstofflöslichen hydrocarbylaluminoxanen
DE69520208D1 (de) Herstellung von nicht-zeolithischen molekularsieben
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
FI980862A0 (fi) Kiraalisia metyylifenyylioksatsolidinoneja
FI973571A0 (fi) Uusi kasvutekijä ja sitä koodaava geneettinen sekvenssi
PE23796A1 (es) Monomeros, oligomeros y polimeros fotoactivos y su obtencion
ATE237568T1 (de) Neue substanzbibliothek und damit hergestellte supramolekulare komplexe
MY109060A (en) New derivatives of b-amino acids
IT1284002B1 (it) Macchina circolare monocilindrica per calzetteria o maglieria particolarmente per la produzione di manufatti chiusi in
DE69915690D1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
IT1314768B1 (it) Processo per la produzione di additivi antifiamma per composizionipolimeriche,e prodotti ottenuti da detto processo
NO20021573L (no) Tverrbundne kopolymerer basert på ikke-tverrbundne polykarboksyl-kopolymerer
FR2711985B1 (fr) Produit poly(glycidyl-azide) non détonant.
DE69623700D1 (de) Turbomolekularpumpe
DE69514122D1 (de) Lösungsmittelfreies verfahren zur herstellung von 2,6 difluorbenzonitril
DE69528890D1 (de) Verwendung von substituierten dextranen zur behandlung von schädigungen des nervensystems, und fraktionen mit erhöhtem heparansulfat-gehalt
ATE166334T1 (de) Verfahren zur herstellung von 3-aryl-propinen und neue 3-aryl-propine
GR1001635B (el) Μέ?οδος παρασκευής 3-[2-(διμε?υλαμινο)-αι?υλο]-ν-με?υλο-1η-ινδόλης-5-με?ανοσουλφοναμίδης.
ATE330491T1 (de) Lagerstabiles produkt auf basis von eiern, und verfahren seiner herstellung
IT231723Y1 (it) Montatura per lumi elettrici, specialmente da tavolo.